12. Remodulin

United Therapeutics expects competition to its top med, Remodulin, this year. (Wikipedia user Farragutful)

Company: United Therapeutics
2017 global sales: $671 million
Disease: Pulmonary arterial hypertension
Patent expiration: June 26

For a smaller pharma company like United Therapeutics, losing patent protection on a big drug is especially painful. Remodulin, approved in 2002, loses exclusivity this summer, meaning the company will soon face off against cheap competition to its biggest top-line contributor.

The drug pulled in $671 million globally last year, United Therapeutics reported, or about 39% of the company’s total sales. Under a 2015 patent settlement, Novartis’ Sandoz can launch its version of the PAH injection on June 26. Sandoz is the only company to boast a tentatively approved generic, according to [email protected]

Teva, Par and Dr. Reddy's could launch their own generics in December, United Therapeutics reported in an annual filing.

Meanwhile, United has won approval for Orenitram, a follow-up to Remodulin that pulled in $185 million last year.

Remodulin isn’t the only hit expected for United Therapeutics this year, either. Adcirca, a PAH med that racked up $420 million in 2017, is slated to face generic rivals in May, according to the drugmaker.

United Therapeutics derives a full 89% of its revenue from U.S. sales, according to its annual securities filing. In reporting 2017 results, the company didn’t break out its U.S. sales for Remodulin.

12. Remodulin

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.